MOTS-c Peptide Alleviates Inflammatory Pain Through Dual Central and Peripheral Actions
Background
Chronic inflammatory pain, characterized by persistent discomfort and increased sensitivity to stimuli, significantly impacts quality of life for millions globally. Current treatments often come with substantial side effects or limited efficacy, highlighting an urgent need for novel therapeutic strategies. This study addresses the critical knowledge gap regarding the potential role of the mitochondrial-derived peptide MOTS-c in modulating pain pathways and its underlying mechanisms.
Results
The study revealed that MOTS-c significantly attenuated inflammatory pain hypersensitivity through both central and peripheral administration. Peripheral 5 mg/kg MOTS-c treatment resulted in a 43% increase in paw withdrawal latency and a 68% increase in mechanical allodynia threshold compared to vehicle-treated controls (p<0.001). Central 0.5 mg/kg MOTS-c administration demonstrated even more potent effects, leading to a 75% increase in mechanical allodynia threshold (p<0.0001).
Why It Matters
The findings suggest that MOTS-c holds significant promise as a novel therapeutic agent for managing inflammatory pain, leveraging its ability to act on both central and peripheral pain pathways. This dual mechanism of action could potentially offer a more comprehensive and effective pain relief strategy compared to existing treatments. Further preclinical development and subsequent human clinical trials are warranted to explore MOTS-c's full therapeutic potential and safety profile, potentially leading to a new class of analgesics.